Recent Updates — RFL

Rafael Holdings reported a net loss attributable to common stockholders of $9.2 million, or $0.18 per share, for the fourth quarter ended July 31, 2026, compared to a $12.1 million loss in the prior year period. Full-year fiscal 2026 results showed a net loss of $29.6 million, or $0.58 per share, versus $30.5 million in the previous year. The company also announced that its subsidiary, Cyclo Therapeutics, submitted a New Drug Application to the FDA for remibetadex (Trappsol® Cyclo™) to treat Niemann-Pick Disease Type C. Rafael Holdings is a biotechnology company that develops pharmaceuticals and holds interests in clinical-stage companies.

Rafael Holdings announced topline results from its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo in Niemann-Pick Disease Type C. The primary endpoint did not achieve statistical significance (p=0.19), though a prespecified analysis of patients on background therapy showed a significant benefit (p=0.046). An overall survival analysis indicated an 85% reduction in mortality risk compared to external controls. The company remains on track to submit a New Drug Application to the FDA in the fourth quarter of 2026. Rafael Holdings is a biotechnology company that develops pharmaceuticals and holds interests in clinical-stage companies.

Rafael Holdings, Inc. announced its results of operations for the fiscal quarter ended April 30, 2026, via an earnings release on June 11, 2026. The company is a provider of technology and services in the technology sector.

Rafael Holdings, Inc. announced that the last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C. Topline data from the main study cohort is expected to be announced in the second half of 2026. Rafael Holdings, Inc. is a biotechnology company focused on developing therapeutic treatments for rare diseases.